GO
Loading...

Enter multiple symbols separated by commas

Stocks Eli Lilly and Co

More

  • Sept 1- Amgen Inc said its experimental bone drug was found to be more effective than an already marketed drug in a late-stage study. Amgen's drug, romosozumab, met the main goal of showing a significant difference over Eli Lilly& Co's teriparatide in improving total hip bone density by the 12th month in postmenopausal women with osteoporosis.

  • LONDON, Sept 1- Novartis and Amgen are joining forces in the hunt for an Alzheimer's treatment, in the latest sign that drugmakers believe an effective therapy for the memory-robbing disease may be within reach. Swiss-based Novartis said on Tuesday the alliance was part of a drive to build up its portfolio in neuroscience, following other deals this summer that...

  • Insulin infusion device maker CeQur raises $100 mln Tuesday, 1 Sep 2015 | 6:53 AM ET

    LONDON, Sept 1- Privately held company CeQur, which is developing the world's first three-day insulin infusion device for people with type 2 diabetes, has raised $100 million in a funding round that shows strong investor appetite for hot medical technology. The patch-like insulin infusion device offers an alternative to daily insulin injections made by the...

  • INDIANAPOLIS— Shares of Eli Lilly rose Wednesday in premarket trading a day after the drugmaker said a federal court upheld a patent protecting one of its top-selling drugs, the cancer treatment Alimta. The Indianapolis company said Tuesday after markets closed that the U.S. District Court for the Southern District of Indiana ruled in Lilly's favor...

  • Aug 20- A new diabetes pill from Eli Lilly and Co and Boehringer Ingelheim cut risk of heart attack, stroke and death in a closely watched study, the first glucose-lowering drug to show such protective results in a large cardiovascular trial, the drugmakers said on Thursday. Besides burnishing the image of the year-old drug, Jardiance, the results could raise the...

  • Aug 7- Eli Lilly on Friday was cleared of liability in the first trial involving claims that its antidepressant Cymbalta caused severe withdrawal symptoms, including suicidal thoughts and electric shock-like sensations, the company said. Eli Lily has been sued by roughly 250 plaintiffs who say that the company downplayed warnings about symptoms that can...

  • Pfizer Inc, which is lagging rivals in the lucrative field of cancer immunotherapies, has been the first to report early data of an "accelerator" treatment that targets a protein called 4-1 BB. Bristol-Myers Squibb Co is hot on Pfizer's heels with a handful of early-stage trials of its own 4-1 BB antibody. Holbrook Kohrt, a researcher from Stanford University...

  • China gets tougher for Western drugmakers Thursday, 6 Aug 2015 | 7:42 AM ET

    *China now world's second biggest drugs market after U.S. *Novo Nordisk latest firm to suffer from China slowdown. Denmark's Novo Nordisk, the world's biggest insulin maker, was the latest to disappoint on Thursday with a 6 percent slide in Chinese sales.

  • Aug 5- CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis. The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight...

  • Aug 5- CVS Health Corp, which operates the nation's second-biggest pharmacy benefit manager, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including Viagra and widely used treatments for diabetes and multiple sclerosis. The 2016 excluded drugs, disclosed on Wednesday, also include Vivus Inc's weight...

  • "It's very significant for us," Chief Executive Andrea Pfeifer told Reuters. It had disappointing results in a mid-stage trial last year but Roche has been encouraged by the promise of drugs from Eli Lilly and Biogen that work in a similar way and believes it can do better by raising the dose. AC Immune, backed by SAP co-founder Dietmar Hopp, received an undisclosed...

  • July 23- Eli Lilly and Co's quarterly sales rose for the first time in seven quarters, helped by demand for its new diabetes and cancer drugs as well as the acquisition of Novartis AG's animal health business. Lilly's net profit fell to $600.8 million, or 56 cents per share, from $733.5 million, or 68 cents per share, a year earlier. It also bumped up the lower end of its...

  • July 23- Eli Lilly and Co said its quarterly revenue rose about 1 percent, helped by demand for its new cancer and diabetes treatments and the acquisition of Novartis AG's animal health business. The Indianapolis- based drugmaker's net profit fell to $600.8 million, or 56 cents per share, in the second quarter ended June 30, from $733.5 million, or 68 cents per share, a...

  • Brace yourself! Thursday is earnings palooza Thursday, 23 Jul 2015 | 6:13 AM ET
    Trader on the floor of the New York Stock Exchange.

    Amazon.com, Caterpillar, McDonald's and GM are among the 50 odd companies reporting Thursday, making it the busiest day of the earnings season.

  • Brace yourself! Thursday is earnings palooza Wednesday, 22 Jul 2015 | 6:35 PM ET
    Trader on the floor of the New York Stock Exchange.

    Amazon.com, Caterpillar, McDonald's and GM are among the 50 odd companies reporting Thursday, making it the busiest day of the earnings season.

  • Biogen, Eli Lilly shares fall on Alzheimer's drug results Wednesday, 22 Jul 2015 | 9:57 AM ET
    Employees at Biogen Idec in Cambridge, MA

    Biogen's Alzheimer's drug showed promise in its latest study, Chief Medical Officer Alfred Sandrock said.

  • Your first trade for Tuesday Monday, 20 Jul 2015 | 6:39 PM ET

    The "Fast Money" traders give their final trades of the day.

  • Alzheimer's drugs on horizon: How do they work? Sunday, 19 Jul 2015 | 1:00 PM ET
    Senior couple with eyes closed

    Medicines in development at Biogen and Eli Lilly could be the first to slow the cognitive declines brought by Alzheimer’s disease. How do they work?

  • A 'Goldilocks' dose for Biogen's Alzheimer's drug? Friday, 17 Jul 2015 | 1:08 PM ET
    A worker in a Biogen lab.

    Biogen is looking to settle on one key thing: the perfect dose for its experimental Alzheimer's drug.

  • DUBLIN, July 16- Britain's Immunocore completed Europe's largest ever financing round by a private life sciences company on Thursday, raising $320 million from investors including Eli Lilly& Co, Malin and Woodford Investment Management. The investment by some of the healthcare sector's "most highly regarded international institutions" is another...